Artificial intelligence (AI) and machine learning (ML) are no longer fringe experiments in healthcare. They are moving into hospitals and research labs worldwide, powering precision medicine, faster diagnoses and data-driven decisions that are already reshaping the way patients are treated.
The push comes from one of medicine’s oldest problems: late detection of deadly diseases such as cancer and heart conditions. Human-led diagnostics have long been practised worldwide, but they often carry the risk of error. AI and ML flip that model, scanning massive datasets from imaging to genetic codes with speed and accuracy. The result is earlier intervention and higher survival chances.
Researchers are now exploring the new frontiers. Among them is Sharmin Sultana Akhi of Monroe University, USA, whose work spans cancer, chronic illness and infectious diseases. Learning Meets Early Diagnosis” shows how hybrid neural networks can sharpen lung cancer predictions. She has also tested ensemble learning to better identify hepatitis C risk groups and combined blockchain with AI to cut prescription errors.
Her research extends to predictive models for kidney disease, thyroid cancer recurrence and decentralised cardiovascular risk assessment. All are built on one principle- give doctors faster, safer decision-making tools while protecting patient privacy.
Akhi has also shifted her focus to drug discovery, where time and expenditure frequently hinder breakthroughs. In “Artificial Intelligence–Enhanced Quantum Computing for Medical Simulations”, she suggests quantum models could accelerate testing of complex drug interactions.
She has also explored how AI can optimise hospital operations, reduce costs, and improve efficiency. It demonstrates how technology’s influence extends well beyond diagnostics. The researcher helps decide which findings gain attention, shaping global debate on how AI should be applied in medicine.
That debate is intensifying in international forums such as IEEE conferences, where disease prediction, blockchain applications and AI-driven diagnostics dominate discussions. The message is clear: AI and ML are no longer side projects. They are becoming pillars of healthcare systems worldwide.
The road ahead is not without obstacles. Implementation hurdles and regulatory questions remain, but the momentum is undeniable. From managing chronic disease to widening access to treatment, AI is not just supporting healthcare. It is redefining it.
